OnkoSightTM Next Generation Sequencing
OnkoSightTM is GenPath’s proprietary product line of Next-Generation Sequencing (NGS) assays for hematologic malignancies and solid tumors that focuses on only actionable mutations in common cancers. This targeted approach helps personalize patient treatment and management while greatly reducing the number of unclear variants that often occur in the results of broader test panels.
Genes included on OnkoSightTM panels are those with clear therapeutic, diagnostic, or prognostic value and those for which there are late-stage clinical trials available. National guidance-recommended genes are included on each tumor-specific panel.